Antibacterial Agents TRIZ Cases

PASTA kinase inhibitors exploit structural differences to target bacterial enzymes with high specificity.

Sulfoximine inhibitors bind to the ENPP1 active site, preventing nucleotide degradation and restoring immune signaling pathways.

Targeting the DLL4 ligand via high affinity binding proteins inhibits tumor angiogenesis while avoiding toxicity from direct Notch receptor inhibition.

Indazole compounds inhibit CCR4 receptor activity, addressing the lack of effective small molecule antagonists for inflammatory disorders.

Poloxamer-protein particles prevent burst release and aggregation by mediating the interface between proteins and PLGA matrices.

Synthetic disaccharides mimic chitin structure to inhibit chitinases, resolving unknown mechanisms of natural inhibitors while minimizing environmental impact.

Formula I compounds bind the human STING dimer interface, resolving species-specific activation limits that blocked prior therapies.

Labelled aryl-sulphonamido inhibitors selectively bind pathological MMPs to enable diagnostic visualization while preserving physiological tissue remodelling.

Alkali metal salt formation resolves low solubility and bioavailability bottlenecks in CCR4 inhibitors.

Segmenting Compound A into distinct crystalline forms resolves manufacturing complexity while ensuring chemical stability and therapeutic effectiveness.

A photosensitizing agent disrupts endocytic vesicles upon light irradiation to release antibacterial agents into the cytosol.

Segmenting carriers into peptides and lipidoids boosts transfection while lowering toxicity.

Citric acid buffers killed Leptospira vaccines to maintain antigenic mass at 37°C, eliminating refrigeration dependency.

Isolated Bolespleenin peptide disrupts bacterial cell walls to treat infections while avoiding antibiotic resistance development.

Maltodextrin and trehalose protect microbiota during lyophilization, enabling stable oral FMT without invasive procedures.

Specific lactylate compounds modify rumen fermentation patterns to reduce methane emissions while improving fecal consistency and udder health.

Modifying oxazolidinone substituents overcomes bacterial resistance mechanisms while maintaining reliable treatment efficacy.

Targeted vaccines neutralize P. acnes virulence factors to prevent acne progression and reduce inflammatory lesions.

Segmenting synthesis to isolate a zwitterionic intermediate removes metal impurities before ring closure, reducing chromium toxicity.

Hybrid compounds target the shikimate pathway to overcome antibiotic resistance in Helicobacter pylori and Mycobacterium tuberculosis infections.

Targeting Factor B with specific inhibitors blocks the alternative complement pathway, addressing limited efficacy of existing anti-VEGF treatments.

Alkyl substitution on the nitazoxanide core resolves the contradiction between treatment effectiveness and adverse effects on intestinal probiotics.

Glycine-serine linkers connect Factor H fragments to Fc regions, resolving low manufacturing yield while preserving pathogen binding affinity.

Tetrazole-substituted arylamides modulate P2X3 and P2X2/3 receptors, addressing inadequate treatments for pain and genitourinary disorders.

Targeted phage cocktails eliminate specific livestock pathogens without contributing to antibiotic resistance, offering a reliable prophylactic alternative.

Modified celecoxib compounds act as bacteriostatic agents against multi-drug resistant Staphylococcus aureus strains.

A vaccine composition entraps antigens within a carrier protein matrix to elicit robust IgG antibody responses.

A chitosan cream formulation accelerates wound healing and skin regeneration through sustained API release.